>>> US Gapping up

Gapping up
In reaction to earnings/guidance:

  • SFIX +36.2% (also names former AMZN exec as CFO), SMAR +18.3% (also names new CFO), GIII +8%, FISV +4.7% (guidance update), COUP +4.6%, CMD +4.3%, NOMD +2.8% (guidance), QGEN +2.1% (Q4 guidance), UMC +1.9% (Nov sales), THO +1.7%, INTU +0.8% (updates guidance to include Credit Karma acquisition)

Other news:

  • HOLI +18.7% (receives preliminary non-binding acquisition proposal for $15.47/sh)
  • TEDU +17.5% (receives preliminary non-binding proposal to acquire the company for $4.00 per ADS from its founder/Chairman)
  • FUTU +10.7% (announced that a global investment firm has agreed to purchase ~50 mln Class A ordinary shares in the form of prepaid warrants for ~US$260 mln)
  • QURE +6.9% (provides data from Phase IIb Study of Etranacogene Dezaparvovec and data for AMT-060; presents initial data from its Phase III HOPE-B gene therapy trial of etranacogene dezaparvovec for the treatment of patients with severe and moderately severe hemophilia B)
  • BKE +5.5% (authorizes $2.00 per share special cash dividend (declared special dividend of $1.25/share last year))
  • GOGO +5% (S&P upgrades to 'B-' from 'CCC+' following sale of commercial aviation business; outlook stable)
  • ON +4.5% (names new CEO)
  • GILT +4.4% (receives multi-million-dollar order for a US Department of Defense tactical communications program)
  • MC +3.8% (declares special dividend of $2.00/sh)
  • AZUL +3.7% (reports November traffic)
  • NYMT +3.5% (increases dividend)
  • X +3.5% (to acquire remaining equity of Big River Steel for approx. $774 mln from cash on hand)
  • SOL +3.2% (announced that China's Ministry of Finance recently approved ten of the Company's rooftop projects to receive incentive payments; expects to receive payments in 2021)
  • BLUE +2.8% (provides update on LentiGlobin Gene Therapy at ASH meeting)
  • KPTI +2.4% (presents new XPOVIO data at ASH meeting)
  • BIDU +2.4% (upsizes share repurchase program to $4.5 bln from $3 bln)
  • ATHA +2% (awarded research grant expected to total $15 mln over 3 years to support ACT-AD clinical trial in Alzheimer's disease)
  • FL +1.4% (adopted a short-term shareholder rights plan and declared a dividend distribution of one right on each outstanding share of the Company's common stock)